Exact Sciences Soars on $2.15 Billion Deal for Testing Firm, , on October 27, 2020 at 4:44 pm

By ILP
On 10/27/2020
In Financial News
Tags:

(Bloomberg) — Exact Sciences Corp. said it will acquire Thrive Earlier Detection Corp. to gain technology for cancer screening in a deal worth as much as $2.15 billion.The cash and stock agreement will bring closely held Thrive’s CancerSeek technology to Exact Sciences, helping establish the Madison, Wisconsin-based company as a competitor in blood-based, multi-cancer screening, according to a statement. Exact Sciences jumped as much as 22% to $130, its highest since the shares began trading in 2001.Testing companies are increasingly developing liquid biopsies that sift through patients’ blood for early signs of tumors, hoping to help doctors begin treatment before the disease gets out of control. Exact Sciences’ acquisition marks the third such deal this year. Last month, Illumina Inc. snapped up Grail Inc. for roughly $8 billion ahead of its initial public offering while in June Invitae Corp. picked up another private company planning to go public, ArcherDx Inc., for about $1 billion.Exact Sciences’ deal is a “bargain” compared to Illumina’s, according to Vijay Kumar, an Evercore ISI analyst. The acquisition “removes the bear thesis that Exact Sciences could be cannibalized by liquid biopsy tests,” he wrote in a research note. The market for a simple blood test that can detect cancers is enormous, with some analyst estimates putting it at $30 billion or more.CancerSeek looks for gene mutations and other markers that can potentially help spot several forms of cancer. The merger will lead to improvements in the accuracy of CancerSeek and get the test in front of doctors and patients faster, Exact Sciences Chief Executive Kevin Conroy said in a phone interview.Conroy and Thrive expect to start a large registrational study likely including tens of thousands of patients next year. The trial will target multiple different cancer types and the effort will likely take years “to do the right way,” Conroy said.The pursuit of a viable cancer detection test is a crowded one. Also racing alongside Exact Sciences, Illumina and Invitae are Guardant Health Inc. and closely-held Freenome Inc. “Cancer is the number two cause of death in the U.S.,” Conroy said. “There will be multiple tests.”Exact Sciences was an early backer of Thrive.Under the terms of the agreement, Thrive will receive $1.7 billion at the deal’s closing, with 65% in Exact Sciences common stock and 35% in cash, subject to certain adjustments. Thrive would receive an additional $450 million based on reaching goals in developing its testing technology. The deal is expected to close in the first quarter of 2021.Exact Sciences also announced a deal for Base Genomics Ltd. for $410 million to expand its testing technology.(Adds CEO Conroy’s comments from fifth paragraph on)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.,

Exact Sciences Soars on $2.15 Billion Deal for Testing Firm(Bloomberg) — Exact Sciences Corp. said it will acquire Thrive Earlier Detection Corp. to gain technology for cancer screening in a deal worth as much as $2.15 billion.The cash and stock agreement will bring closely held Thrive’s CancerSeek technology to Exact Sciences, helping establish the Madison, Wisconsin-based company as a competitor in blood-based, multi-cancer screening, according to a statement. Exact Sciences jumped as much as 22% to $130, its highest since the shares began trading in 2001.Testing companies are increasingly developing liquid biopsies that sift through patients’ blood for early signs of tumors, hoping to help doctors begin treatment before the disease gets out of control. Exact Sciences’ acquisition marks the third such deal this year. Last month, Illumina Inc. snapped up Grail Inc. for roughly $8 billion ahead of its initial public offering while in June Invitae Corp. picked up another private company planning to go public, ArcherDx Inc., for about $1 billion.Exact Sciences’ deal is a “bargain” compared to Illumina’s, according to Vijay Kumar, an Evercore ISI analyst. The acquisition “removes the bear thesis that Exact Sciences could be cannibalized by liquid biopsy tests,” he wrote in a research note. The market for a simple blood test that can detect cancers is enormous, with some analyst estimates putting it at $30 billion or more.CancerSeek looks for gene mutations and other markers that can potentially help spot several forms of cancer. The merger will lead to improvements in the accuracy of CancerSeek and get the test in front of doctors and patients faster, Exact Sciences Chief Executive Kevin Conroy said in a phone interview.Conroy and Thrive expect to start a large registrational study likely including tens of thousands of patients next year. The trial will target multiple different cancer types and the effort will likely take years “to do the right way,” Conroy said.The pursuit of a viable cancer detection test is a crowded one. Also racing alongside Exact Sciences, Illumina and Invitae are Guardant Health Inc. and closely-held Freenome Inc. “Cancer is the number two cause of death in the U.S.,” Conroy said. “There will be multiple tests.”Exact Sciences was an early backer of Thrive.Under the terms of the agreement, Thrive will receive $1.7 billion at the deal’s closing, with 65% in Exact Sciences common stock and 35% in cash, subject to certain adjustments. Thrive would receive an additional $450 million based on reaching goals in developing its testing technology. The deal is expected to close in the first quarter of 2021.Exact Sciences also announced a deal for Base Genomics Ltd. for $410 million to expand its testing technology.(Adds CEO Conroy’s comments from fifth paragraph on)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

,

Contact Us

Please use our Instant Quote form to see if you're pre-qualified for a non-recourse stock loan, or if you have any questions or feedback, please email, call or chat with us.

deals@internationalliquiditypartners.com

+44 20 3994 1588

Headquarters: Hunkins Waterfront Plaza, Charlestown, Nevis

Open 24 hours a day / 7 days a week / 365 days a year

 

 

 

Frequently Asked Questions

What Is Securities-Based Lending?
Securities-based lending, or a stock loan, is the practice of using market investments such as stocks, ETF’s, warrants, bonds, or real estate investment trusts as collateral for a loan.
How much money can I get for my securities?
Borrow up to 80% of the value of your pledged investments giving you the capital you need to expand your business, purchase real estate, or tackle a costly project.
What happens if my securities lose value?
With a non-recourse stock loan, you can walk away from your securities at any time and keep the loan money with no negative credit consequences even if the investments lose value.
Is my information safe with ILP?
We pride ourselves on outstanding service and make client confidentiality our top priority. You can always be absolutely certain your information is safe with us.
How long does it take for the disbursement of funds?
Most of the transactions we process take less than 7 days from application to the disbursement of funds giving you cash quickly when you need it most.
What credit score do I need to qualify?
There are no credit checks or personal guarantees necessary with our services. Your pledged securities are the only collateral required for the loan you receive.

Instant Quote

Please fill out your information to see if you are pre-qualified.

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

International Liquidity Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

International Liquidity Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with International Liquidity Partners, LLC’s internal lending policies. International Liquidity Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Nevis Office

Main Street
Hunkins Waterfront Plaza
Charlestown, Nevis

New York Office

Coming Soon!

Follow Us

Market Coverage